Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis DNA vaccines.

J B Ulmer1

  • 1Department of Vaccines Research, Chiron Corporation, Emeryville, California 94608, USA.

Scandinavian Journal of Infectious Diseases
|May 10, 2001
PubMed
Summary
This summary is machine-generated.

New DNA vaccine technologies show promise for tuberculosis prevention. While human trials have faced potency challenges, advancements in formulations and delivery systems offer a clear path toward effective DNA vaccines for tuberculosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA vaccines.

Methods in molecular medicine·2011
Same author

Mechanisms of action of DNA vaccines.

Expert opinion on investigational drugs·2005
Same author

Attenuated salmonella and Shigella as carriers for DNA vaccines.

Journal of drug targeting·2004
Same author

Priming of CTL responses by DNA vaccines: direct transfection of antigen presenting cells versus cross-priming.

Developments in biologicals·2001
Same author

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.

Journal of virology·2001
Same author

An update on the state of the art of DNA vaccines.

Current opinion in drug discovery & development·2001
Same journal

Fas-Ligand Mediated Apoptosis in Severe Sepsis and Shock.

Scandinavian journal of infectious diseases·2017
Same journal

Lipopolysaccharide-inducible Gene Expression Profile in Human Monocytes.

Scandinavian journal of infectious diseases·2017
Same journal

Fatal varicella pneumonia.

Scandinavian journal of infectious diseases·2015
Same journal

Wissler's Syndrome Associated with Parainfluenza 2 Infection.

Scandinavian journal of infectious diseases·2015
Same journal

Contamination of smears with "sergentella spiroides".

Scandinavian journal of infectious diseases·2015
Same journal

Recrudescent typhus: fluctuations in titers of complement-fixing and microagglutinating antibodies to rickettsia prowazeki in persons with a history of epidemic typhus.

Scandinavian journal of infectious diseases·2015
See all related articles

Area of Science:

  • Vaccinology
  • Immunology
  • Microbiology

Background:

  • DNA vaccines have been researched for over a decade, with several tuberculosis (TB) DNA vaccines demonstrating efficacy in animal models.
  • Human trials of naked DNA vaccines (e.g., for malaria) have shown proof of principle for immune priming but are limited by potency.
  • Significant progress is being made in developing new DNA vaccine formulations and delivery systems.

Purpose of the Study:

  • To review the progress and potential of DNA vaccines for tuberculosis.
  • To highlight advancements in DNA vaccine technology addressing potency limitations.
  • To assess the feasibility of human clinical testing for TB DNA vaccines.

Main Methods:

  • Review of existing research on DNA vaccine development for tuberculosis.

Related Experiment Videos

  • Analysis of preclinical and clinical data on DNA vaccine potency and efficacy.
  • Evaluation of novel formulations and delivery systems for DNA vaccines.

    • Main Results:

    • Multiple TB DNA vaccine candidates have shown protective immunity in animal models.
    • Human trials have confirmed the ability of DNA vaccines to prime immune responses.
    • Newer DNA vaccine formulations and delivery systems exhibit markedly improved potency in animal studies.

    Conclusions:

    • Advancements in DNA vaccine technology offer a promising future for tuberculosis prevention.
    • Improved potency in animal models suggests a viable path for human clinical trials of TB DNA vaccines.
    • Further development and testing are warranted to translate these findings into effective human vaccines.